To advance this research towards commercialization, Daniel Fologea benefits from an NSF Transform grant for marketed oriented ...

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ:AZN) said on Friday that Enhertu received European Union approval for the ...

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.

Compass Therapeutics (CMPX) announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, the Company’s ...

The dose of paclitaxel used in the new approach was 16-fold lower than that typically used in free paclitaxel, but with similar efficacy.